Halaven (Eribulin Mesylate) Patent Expiration, LOE Window & CMS Spending

Halaven (Eribulin Mesylate) by Eisai: FDA Orange Book LOE 2027-07-08, 0 AB generics, $5.1M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorEisai
FDA Application & PathwayN201532 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2027-07-08
Orange Book Patents (*PED Extensions)2 patents (1 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$5.1M
2024 Medicare Part D Spend$281K
2024 Medicaid Spend$4.8M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eisai across sibling Meru public-data platforms.